St. Louis biotech Immunophotonics has received a European patent covering the use of its lead drug candidate IP-001 in combination with checkpoint inhibitors for the treatment of solid tumors, expanding the company’s global intellectual property portfolio to more than 20 European countries. “IP-001 has demonstrated promising results in preclinical studies and is currently being evaluated […]
Paul Riat is just this guy, trying to figure things out. A fan of Max Weber, he generally gets a kick out of the triangle between economy, society and liberty. His focus on technology startups and venture capital fits because early stage tech startups are the most dynamic and impactful elements of local economies -- improving liberty and society like a rising tide.
